We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Optimizing Starting Material Quality for Cellular Therapeutics

Article   Aug 03, 2018 | by Dominic Clarke, PhD and Marie Aragon, RN, BSN. HemaCare Corporation

 
Optimizing Starting Material Quality for Cellular Therapeutics

Credit: Terumo BCT

 
 
 

RELATED ARTICLES

A Micro-revolution with Giant Benefits

Article

With more and more applications of the microfluidics industry becoming apparent, giving scientists the tools they need has never been more important. This article highlights major industries that benefit from microfluidic technology, and provides insights into how demands for microfluidic components are changing.

READ MORE

The Biosimilars Market is Likely to Grow at a Compound Annual Growth Rate of 49.1% from 2015 to 2020

Article

The global biosimilars market was valued at $2,552.0 million in 2014 and is expected to reach $26,551.3 million by 2020, supported by a compound annual growth rate (CAGR) of 49.1% during the forecast period 2015 to 2020, according to Allied Market Research’s report.

READ MORE

Cancer Cells vs Normal Cells

Article

Cancer is a complex genetic disease that is caused by specific changes to the genes in one cell or group of cells. These changes disrupt normal cell function – specifically affecting how a cell grows and divides. This article outlines some of the key differences between cancer cells and normal cells.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Biopharma Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE